Key Points
- CFO James Frates sold 3,326 shares on Jan. 6 at an average price of $11.11 for $36,951.86, trimming his stake to 177,104 shares (a 1.84% decrease) valued at about $1.97 million.
- Analyst views are mixed but generally positive on average, with a MarketBeat consensus of "Moderate Buy" and an average target of $17.25, while Citi and Guggenheim raised targets to $20 and $25 respectively despite some sell ratings.
- Institutional ownership is very high (95.84%), led by large positions from Adage, Perceptive Advisors, TCG Crossover and Vanguard, indicating concentrated insider and institutional holdings.
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) CFO James Frates sold 3,326 shares of the firm's stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $11.11, for a total transaction of $36,951.86. Following the completion of the transaction, the chief financial officer directly owned 177,104 shares of the company's stock, valued at $1,967,625.44. This represents a 1.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Amylyx Pharmaceuticals Price Performance
AMLX opened at $11.83 on Friday. The business has a fifty day moving average price of $13.05 and a 200 day moving average price of $11.26. Amylyx Pharmaceuticals, Inc. has a 12 month low of $2.60 and a 12 month high of $16.96. The stock has a market capitalization of $1.30 billion, a price-to-earnings ratio of -6.57 and a beta of -0.31.
Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.06. On average, research analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current year.
Analysts Set New Price Targets
A number of analysts have weighed in on the company. Citigroup raised their price target on Amylyx Pharmaceuticals from $12.00 to $20.00 and gave the company a "buy" rating in a research note on Friday, October 17th. Wall Street Zen lowered Amylyx Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, December 20th. Weiss Ratings restated a "sell (d-)" rating on shares of Amylyx Pharmaceuticals in a research note on Monday, December 29th. Lifesci Capital upgraded shares of Amylyx Pharmaceuticals to a "strong-buy" rating in a research note on Monday, October 27th. Finally, Guggenheim lifted their price target on shares of Amylyx Pharmaceuticals from $17.00 to $25.00 and gave the stock a "buy" rating in a research note on Monday, September 15th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $17.25.
Read Our Latest Stock Report on Amylyx Pharmaceuticals
Institutional Investors Weigh In On Amylyx Pharmaceuticals
A number of institutional investors and hedge funds have recently modified their holdings of the company. Adage Capital Partners GP L.L.C. raised its holdings in Amylyx Pharmaceuticals by 54.5% during the second quarter. Adage Capital Partners GP L.L.C. now owns 8,800,000 shares of the company's stock worth $56,408,000 after purchasing an additional 3,102,395 shares during the last quarter. Perceptive Advisors LLC increased its stake in shares of Amylyx Pharmaceuticals by 0.4% during the 2nd quarter. Perceptive Advisors LLC now owns 7,902,365 shares of the company's stock worth $50,654,000 after purchasing an additional 28,017 shares in the last quarter. TCG Crossover Management LLC boosted its stake in shares of Amylyx Pharmaceuticals by 5.0% during the third quarter. TCG Crossover Management LLC now owns 6,243,812 shares of the company's stock valued at $84,853,000 after acquiring an additional 300,000 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Amylyx Pharmaceuticals by 17.2% during the third quarter. Vanguard Group Inc. now owns 5,273,750 shares of the company's stock worth $71,670,000 after buying an additional 775,722 shares in the last quarter. Finally, Commodore Capital LP purchased a new stake in Amylyx Pharmaceuticals in the 3rd quarter worth approximately $55,386,000. Institutional investors and hedge funds own 95.84% of the company's stock.
Amylyx Pharmaceuticals Company Profile
(
Get Free Report)
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.
The company's lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
